Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Alpine Immune Sciences — Net income (loss) by Quarter
Alpine Immune Sciences — Net income (loss) ($M) ($M)
Vertex Pharmaceuticals Alpine Immune Sciences — Net income (loss): -$17.9M in Q1 2024, up 35.0% from a year earlier. No newer figure appears in the documents we track.
Where the Q1 2024 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001626199 Alpine Immune Sciences).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Alpine Immune Sciences — Net income (loss) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q1 2024 | Mar 31, 2024 | -17.9 | +35.0% | SEC Filing ↗ |
| Q4 2023 | Dec 31, 2023 | 5.97 | -131.7% | SEC Filing ↗ |
| Q3 2023 | Sep 30, 2023 | -11.7 | -11.7% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | -13.2 | -27.3% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | -13.3 | +76.2% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | -18.9 | +24.3% | SEC Filing ↗ |
| Q3 2022 | Sep 30, 2022 | -13.3 | -1.6% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | -18.1 | +64.1% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | -7.53 | -29.2% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | -15.2 | +139.3% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | -13.5 | +119.7% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | -11.0 | +11.1% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | -10.6 | +92.4% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | -6.34 | +3.3% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | -6.14 | -46.5% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | -9.93 | -16.3% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | -5.53 | -55.3% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | -6.14 | -44.8% | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | -11.5 | -5.5% | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | -11.9 | +49.9% | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | -12.4 | +133.1% | SEC Filing ↗ |
| Q4 2018 | Dec 31, 2018 | -11.1 | – | SEC Filing ↗ |
| Q3 2018 | Sep 30, 2018 | -12.1 | – | SEC Filing ↗ |
| Q2 2018 | Jun 30, 2018 | -7.91 | – | SEC Filing ↗ |
| Q1 2018 | Mar 31, 2018 | -5.31 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Alpine Immune Sciences — Net income (loss) ($M), quarterly Q1 2018–Q1 2024 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/alpine-net-inc
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.